EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
EQS-News: Formycon AG
/ Key word(s): Study
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announced today that the first patient has been enrolled in the Phase III clinical trial “Lotus” to compare the safety and efficacy of FYB206/pembrolizumab with the immuno-oncology blockbuster drug Keytruda® (First Patient In). The double-blind, multicenter “Lotus” study is evaluating the best overall response rate (bORR) in patients with non-small cell lung cancer (NSCLC). The comparative treatment comprises up to 17 treatment cycles within 40 weeks. Changes in tumor size will be continuously documented during this period using imaging techniques. Following the comparative treatment, the therapy will be continued for an additional 12 months. The study design was developed in close coordination with the regulatory authorities U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The trial is being conducted in several countries in Eastern Europe and Southeast Asia and is running in parallel to the Phase I study, which started in mid-June, comparing the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference drug Keytruda® in patients with malignant melanoma (black skin cancer). “Immuno-oncology is a relatively young field in cancer therapy and is seen as a great hope for many patients. Pembrolizumab has already demonstrated its efficacy in numerous types of cancer. Additionally, several studies are currently underway to expand the range of indications. This alone highlights the enormous potential of our pembrolizumab biosimilar candidate FYB206 – both in medical and economic terms. In fact, sales of Keytruda®, currently the world’s best-selling drug, are also continuing to grow. The start of the Phase III clinical trial represents an important milestone for us in order to provide an effective, safe and cost-effective treatment option for many severely ill cancer patients worldwide in the future,” comments Dr. Andreas Seidl, Chief Scientific Officer (CSO) of Formycon AG. Non-small cell lung cancer is one of numerous cancer diseases for which the immune checkpoint inhibitor pembrolizumab is indicated. In a wide variety of cancers, cancer cells manage to inhibit the body's own immune defenses by manipulating so-called immune checkpoints. Pembrolizumab, which targets the immune checkpoint PD-1, ensures that the body's own T cells can again fight and kill the cancer cells. Due to the increasing use of the active ingredient in earlier stages of cancer and the continuing high global demand, sales of Keytruda® increased by 20% year-on-year in the first quarter of 2024.3 As a result, sales of this currently best-selling drug could rise to USD 30 billion worldwide by 2026.4 Following the completion of clinical development and subject to approval by the regulatory authorities, Formycon currently anticipates the earliest market entry of FYB206 after the expiry of the market exclusivity of the reference product in the USA from 2029 and in the EU from 2030. First results of the Phase I trial are expected in 2026. Preliminary results of the Phase III trial are to follow in the course of 2027. ------------------------------ 1 Keytruda® is a registered trademark of Merck Sharp Dohme LLC, a subsidiary of Merck Co, Inc, Rahway, NJ/USA
About Formycon: About Biosimilars: Contact:
30.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Formycon AG |
Fraunhoferstraße 15 | |
82152 Planegg-Martinsried | |
Germany | |
Phone: | 089 864667 100 |
Fax: | 089 864667 110 |
Internet: | www.formycon.com |
ISIN: | DE000A1EWVY8 |
WKN: | A1EWVY |
Indices: | Scale 30 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1956263 |
End of News | EQS News Service |
|
1956263 30.07.2024 CET/CEST
Formycon AG Aktie
Die Community sieht Formycon AG leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Die Community prognostiziert für Formycon AG ein Kursziel von 100 €, was den aktuellen Kurs von 48.85 € weit übertrifft.